R&D
CAMP4 on a new class of ASO in gene under expression
CAMP4 Therapeutics CFO Kelly Gold discusses developments in antisense oligonucleotides and CAMP4’s CMP-002 study
Patients
Progress with England’s Single National Formulary after a ye...
Leela Barham digs deeper into the progress update from NHS England in July 2026.
R&D
Drug discovery has a human biology problem
The current opportunity lies in optimising existing discovery methodologies by generating more predictive, reproducible human data.
Oncology
Early diagnosis means little without timely treatment
Early diagnosis only changes outcomes if it is followed by timely treatment.
Sales & Marketing
Digital
Market Access
Editor's Picks
Editor's Picks
